Company profile for IM Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

IMT is the first company to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk. The Company platform builds drug molecules for specific blockade of an HLA protein in a given autoimmune disease as a novel paradigm in drug development. Our drug development of oral therapies employs a unique approach to balance the affinity to HLA binding site(s) to achieve bl...
IMT is the first company to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk. The Company platform builds drug molecules for specific blockade of an HLA protein in a given autoimmune disease as a novel paradigm in drug development. Our drug development of oral therapies employs a unique approach to balance the affinity to HLA binding site(s) to achieve blockade versus protecting inherent immunity against pathogens conferred by the HLA proteins.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
299 Washington St. Suite A Woburn, MA 01801
Telephone
Telephone
+1 303.544.2104
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20210721005071/en

BUSINESSWIRE
21 Jul 2021

https://www.fiercebiotech.com/biotech/im-therapeutics-posts-positive-results-for-phase-1b-study-type-1-diabetes

Kyle LaHucik FIERCEBIOTECH
21 Jul 2021

https://www.businesswire.com/news/home/20210624005253/en

BUSINESSWIRE
26 Jun 2021

https://www.businesswire.com/news/home/20210406005260/en/IM-Therapeutics-Expands-Management-Team-with-David-Alleva-Ph.D.-as-VP-Immunology

BUSINESSWIRE
06 Apr 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty